Published in J Clin Oncol on April 20, 2010
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
The impact of next-generation sequencing on genomics. J Genet Genomics (2011) 2.41
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol (2012) 1.56
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology. BMC Syst Biol (2015) 1.39
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn (2014) 1.21
Feasibility and yield of a novel 22-gauge histology EUS needle in patients with pancreatic masses: a multicenter prospective cohort study. Surg Endosc (2013) 1.19
Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol (2012) 1.18
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One (2013) 1.07
Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med (2012) 1.04
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun (2013) 0.99
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
Pharmacogenetics of new analgesics. Br J Pharmacol (2011) 0.95
Proteomics and biomarkers in clinical trials for drug development. J Proteomics (2011) 0.94
Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philos Trans R Soc Lond B Biol Sci (2014) 0.92
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev (2012) 0.92
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res (2012) 0.90
Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother (2012) 0.90
Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res (2013) 0.89
A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS One (2011) 0.88
Advances in proteomic strategies toward the early detection of lung cancer. Proc Am Thorac Soc (2011) 0.87
Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome. J Behav Med (2012) 0.86
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
Mechanistic systems modeling to guide drug discovery and development. Drug Discov Today (2012) 0.86
Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol (2015) 0.85
Functional Genomics Assistant (FUGA): a toolbox for the analysis of complex biological networks. BMC Res Notes (2011) 0.85
Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther (2015) 0.84
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther (2014) 0.84
Major Functional Transcriptome of an Inferred Center Regulator of an ER(-) Breast Cancer Model System. Cancer Inform (2012) 0.83
Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Cancer (2013) 0.81
Systems biology data analysis methodology in pharmacogenomics. Pharmacogenomics (2011) 0.80
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities. Int J Proteomics (2011) 0.78
Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int (2013) 0.78
A microfluidic platform for high-throughput multiplexed protein quantitation. PLoS One (2015) 0.78
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Invest New Drugs (2012) 0.77
The Major Prognostic Features of Nuclear Receptor NR5A2 in Infiltrating Ductal Breast Carcinomas. Int J Genomics (2015) 0.77
Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis. Stat Methods Med Res (2013) 0.76
Clinical trials in cancer. Br J Cancer (2011) 0.76
Trends in Personalized Therapies in Oncology: The (Venture) Capitalist's Perspective. J Pers Med (2012) 0.76
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res (2014) 0.76
Integration of proteomics into systems biology of cancer. Wiley Interdiscip Rev Syst Biol Med (2012) 0.76
Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging (2016) 0.75
A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer. PLoS One (2016) 0.75
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol (2015) 0.75
Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine. Hum Pathol (2014) 0.75
Efficient Switches in Biology and Computer Science. PLoS Comput Biol (2017) 0.75
Coverage of genomic medicine: information gap between lay public and scientists. Risk Manag Healthc Policy (2012) 0.75
Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication? PLoS One (2014) 0.75
Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis. Oncotarget (2016) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Engineering tumors with 3D scaffolds. Nat Methods (2007) 3.96
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol (2002) 3.08
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol (2009) 2.36
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res (1998) 1.87
Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res (2008) 1.63
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene (2007) 1.43
Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic (2002) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 1.18
The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci (2008) 1.15
DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn (2009) 1.01
Tumor dormancy and oncogene addiction. APMIS (2008) 0.96
Targeting cancer-specific synthetic lethality in double-strand DNA break repair. Cell Cycle (2009) 0.90
A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res (2009) 0.88
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res (2005) 3.80
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A (2010) 3.03
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res (2004) 2.32
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta (2002) 2.18
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res (2007) 2.14
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell (2012) 2.11
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A (2010) 2.10
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res (2013) 2.09
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther (2002) 2.03
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Uniparental disomy in cancer. Trends Mol Med (2009) 1.99
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem (2003) 1.97
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem (2003) 1.95
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res (2007) 1.94
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol (2002) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs (2010) 1.85
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res (2009) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
AMPK: a contextual oncogene or tumor suppressor? Cancer Res (2013) 1.82
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80